Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)

Simply Wall St.10-09

Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674343048?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-10-09 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674343048","market":"sg","top_or_hot":-1,"title":"Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)","media":"Simply Wall St.","content":"<div>\n<p>Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-09 14:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","article_id":"2674343048","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2674343048","pubTimestamp":1791528314,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running contract dispute overhang.\nThe same rezpegaldesleukin data set highlights durable responses with less frequent dosing schedules, which directly affects future trial design, treatment positioning, and potential development costs.\nWe will now look at how Nektar Therapeutics' investment narrative...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4139":"生物科技","BK4007":"制药"},"translate_title":"诉讼胜诉可能会改变 Nektar Therapeutics (NKTR) 的游戏规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running contract dispute overhang. The same rezpegaldesleukin data set highlights durable responses with less frequent dosing schedules, which directly affects future trial design, treatment positioning, and potential development costs. We will now look at how Nektar Therapeutics' investment narrative could be reshaped by rezpegaldesleukin's long term durability data.  Spot 20 high quality undiscovered gems that share Nektar Therapeutics' focus on underappreciated pipelines and catalytic trial data, which could reshape how the market values their future potential.\nAdvertisementNektar Therapeutics Investment Narrative Recap To own Nektar Therapeutics, you need to believe rezpegaldesleukin can convert today’s dermatology data into tomorrow’s commercial franchise and partnership leverage. The firm is still pre-commercial and loss making, with R&D and G&A expected to stay heavy, so the key near term catalyst is clean execution as rezpegaldesleukin moves into large Phase 3 programs. The biggest immediate risk is simple. Rezpegaldesleukin is carrying most of the equity story while Nektar funds multi indication trials in a competitive immunology field. The new long term and off treatment durability data tighten the operational focus around Phase 3 trial design and dosing, but they do not remove financing, regulatory, or competition risks. The most relevant fresh development is the one year and off treatment durability data for rezpegaldesleukin in alopecia areata and atopic dermatitis presented at EADV 2026. These results, including maintenance of SALT Score ≤20 up to 6 months after stopping therapy and deepening EASI responses with monthly and quarterly dosing, speak directly to how management may shape Phase 3 protocols. For you as a shareholder, that matters because Nektar Therapeutics is trying to run broader, later stage programs while remaining unprofitable and exposed to dilution and funding constraints. A regimen that supports less frequent dosing and sustained control can influence positioning against JAKs and other biologics, inform potential partners, and frame how rezpegaldesleukin may support the revenue growth analysts are modeling over the next several years. Nektar Therapeutics' current analyst script points to revenue of US$40.0 million and earnings of US$8.8 million by 2029, based on a forecast 9.9% yearly decline in revenue over the next three years and an earnings swing of about US$165.9 million from a loss of US$157.1 million today. Uncover why Nektar Therapeutics' fair value indicates a 254% potential upside to its current price. This opportunity could narrow quickly. NasdaqCM:NKTR 1-Year Stock Price Chart Exploring Other Perspectives One alternate angle to watch is timing. The most cautious analysts focused on the long wait until Phase 3 atopic dermatitis data and a possible 2029 filing, and before this EADV update they were only modeling about US$1.4 million of 2029 revenue and roughly US$301.7 thousand of earnings. That is a far more restrained Nektar Therapeutics story. It shows how sharply opinions can differ and why it can help to compare several viewpoints as this new rezpegaldesleukin durability evidence filters into future models. Explore 2 other Nektar Therapeutics fair value estimates, including one that suggests it could be worth just $141.40! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. See our latest analysis for Nektar Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.  Looking for more investment ideas beyond Nektar Therapeutics? If rezpegaldesleukin has put Nektar Therapeutics on your radar, it can help to widen the lens and compare it with other businesses that share similar traits, whether that is untapped assets, resilient balance sheets, or lower perceived risk.  If you prefer stocks where the market is already rewarding strong cash generation and sturdy finances, check out a list of solid balance sheet and fundamentals (25 results) that can act as a quality filter for your watchlist. For investors hunting for misunderstood opportunities, a 20 high quality undiscovered gems can surface smaller businesses that have robust fundamentals but limited current attention. When capital preservation sits high on your priority list, look through a 31 resilient stocks with low risk scores that screens for companies with more measured risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nektar Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674343048","isCrawlerRequest":true}